title: Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia.
abstract: BACKGROUND
  Hyperglycemia is common during therapy for acute lymphoblastic leukemia (ALL), but diabetic ketoacidosis (DKA) occurs rarely. Morbidity due to DKA in children with ALL has not been systematically studied.
  
  
  METHODS
  We reviewed risk factors and clinical consequences of DKA in patients undergoing therapy for ALL at SJCRH between 1991 and 2006.
  
  
  RESULTS
  DKA occurred in 6 of 797 evaluable patients. Only older age at diagnosis of ALL was a risk factor for DKA. Four of six patients with DKA as compared to 232 of the other 791 patients were older than 10 years (P = 0.03). Race, sex, body mass index, leukemia immunophenotype, ALL risk category, white blood cell count at diagnosis, and treatment protocol were not associated with DKA. All patients were managed with intravenous fluids, dietary modification, and short-term use of insulin. Patients were hospitalized for 4-12 days, with a median ICU stay of 1 day. In two patients, correction of hyperglycemia was too rapid, and two others experienced hypoglycemia due to insulin therapy. There were no permanent complications of DKA or its treatment. No patient required long-term insulin use. No patient had recurrent DKA; only one of the six patients had a subsequent hyperglycemia episode. All six patients are alive in remission 6-13 years after diagnosis.
  
  
  CONCLUSIONS
  Patients with hyperglycemia during treatment for ALL should be screened for clinical evidence of DKA, which may require more intensive supportive care than those without ketoacidosis. The occurrence of DKA should not lead to alteration of ALL treatment.
authors.affiliation: Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. jessica.roberson@stjude.org
authors.forename: Jessica R
authors.initials: JR
authors.lastname: Roberson
authors.forename: Sailaja
authors.initials: S
authors.lastname: Raju
authors.forename: John
authors.initials: J
authors.lastname: Shelso
authors.forename: Ching-Hon
authors.initials: CH
authors.lastname: Pui
authors.forename: Scott C
authors.initials: SC
authors.lastname: Howard
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D016883:Diabetic Ketoacidosis / Q000139:chemically induced / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D005938:Glucocorticoids; D001215:Asparaginase